⌘K
Loading ticker…
As of 2026-08-24, Heron Therapeutics, Inc. (HRTX) has a 3-month relative strength percentile of 4 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 27. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 9.4%, relative volume 0.75×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
HRTX is in a stage 4 downtrend, week 3. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -23.4% / -64.9%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
HRTX is held by 14 ETFs as of May 2026. Top owner: SCHA at 0.00% weight, $757K notional. Top 3 carry $2M.
Held by 24 ETFs · $14M across latest filings · largest weight 0.30% (QQQS).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| SCHASchwab U.S. Small-Cap ETF | 0.00% | $757K | — |
| VTWO | 0.00% | $682K | — |
| VHTVanguard Health Care ETF | 0.00% | $362K | — |
| VTWV | 0.01% | $90K | — |
| SCHBSchwab U.S. Broad Market ETF | 0.00% | $73K | — |
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Related searches
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| QQQS | 0.30% | $56K | −0.19 pp |
| VTWG | 0.00% | $16K | — |
| VTHRVanguard Russell 3000 ETF | 0.00% | $11K | — |
| ITWO | 0.00% | $6K | — |
| URTY | 0.00% | $5K | — |
Showing 10 of 14 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | HRTX Jan avg: 15.70% median: 9.76% win: 100% σ: 17.84% n: 4 2022-04-12 → 2026-07-31 | HRTX Feb avg: 8.32% median: 0.26% win: 50% σ: 26.69% n: 4 2022-04-12 → 2026-07-31 | HRTX Mar avg: -18.96% median: -21.85% win: 25% σ: 19.05% n: 4 2022-04-12 → 2026-07-31 | HRTX Apr avg: 15.91% median: 10.00% win: 60% σ: 37.07% n: 5 2022-04-12 → 2026-07-31 | HRTX May avg: -13.92% median: -26.99% win: 20% σ: 42.68% n: 5 2022-04-12 → 2026-07-31 | HRTX Jun avg: -11.99% median: -5.41% win: 40% σ: 23.72% n: 5 2022-04-12 → 2026-07-31 | HRTX Jul avg: 5.49% median: -0.36% win: 40% σ: 24.85% n: 5 2022-04-12 → 2026-07-31 | HRTX Aug avg: -2.77% median: -11.58% win: 25% σ: 36.06% n: 4 2022-04-12 → 2026-07-31 (current) | HRTX Sep avg: -9.39% median: -1.78% win: 50% σ: 19.10% n: 4 2022-04-12 → 2026-07-31 | HRTX Oct avg: -16.86% median: -10.66% win: 0% σ: 14.35% n: 4 2022-04-12 → 2026-07-31 | HRTX Nov avg: 7.98% median: -14.80% win: 25% σ: 58.58% n: 4 2022-04-12 → 2026-07-31 | HRTX Dec avg: 17.78% median: 20.32% win: 75% σ: 20.15% n: 4 2022-04-12 → 2026-07-31 |